Skip to main content

Press Releases

Date Title
Toggle Summary Sienna Biopharmaceuticals Announces First Patient Dosed in Proof-of-Concept Trial of Topical by Design™ JAK Inhibitor SNA-125 for Atopic Dermatitis
-- Trial to Enroll Approximately 30 Patients with Atopic Dermatitis -- Top-Line Results Expected in Fourth Quarter of 2018 WESTLAKE VILLAGE, Calif. , March 12, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc.  (NASDAQ:SNNA) today announced that the first patient has been dosed in the
Toggle Summary Sienna Biopharmaceuticals Appoints Caroline Van Hove as Chief Commercial Officer
-- Expansion of Leadership Team Enables Sienna to Prepare for Commercial Focus with Five Development Programs Now in the Clinic WESTLAKE VILLAGE, Calif. , March 22, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the appointment of Caroline Van Hove as the
Toggle Summary Sienna Biopharmaceuticals Appoints John W. Smither as Chief Financial Officer
Richard Peterson Departing for Personal Reasons WESTLAKE VILLAGE, Calif. , March 21, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the appointment of John W. Smither as the Company’s Chief Financial Officer. Mr.
Toggle Summary Sienna Biopharmaceuticals Reports First Quarter 2018 Financial Results
WESTLAKE VILLAGE, Calif. , May 14, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the first quarter of 2018. “We are pleased to report the results of our first quarter,” said Frederick C.
Toggle Summary Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
-- Pipeline Includes Five Clinical-Stage Programs -- Data from Five Clinical Programs Expected, Beginning in 2H18 WESTLAKE VILLAGE, Calif. , March 15, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the fourth quarter and

SEC Filings

Events

Webcast events that have already occurred are presented for historical purposes only and speak only as of the date thereof.

Stock Information

Copyright Nasdaq. Minimum 15 minutes delayed.

Refresh quote

Analyst Coverage

Firm Analyst
J.P. Morgan
Chris Schott
Cowen
Ken Cacciatore
BMO Capital Markets
Gary Nachman
Guggenheim Securities
Rohit Vanjani

The analysts above have initiated and are maintaining formal research coverage of Sienna. Please note that any opinions, estimates or forecasts regarding Sienna’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Sienna or Sienna’s management. Sienna does not by reference above or distribution of same imply endorsement of or concurrence with any analyst’s opinions, estimates, forecasts, conclusions or recommendations. Sienna does not participate in the preparation of analysts’ reports and undertakes no obligation to verify or correct any information in such reports.

Transfer Agent

EQ Shareowner Services
www.shareowneronline.com

IR Contact

IR@SiennaBio.com

Media Contact

media@SiennaBio.com